Skip to main content

Market Overview

The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin

The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Stocks hitting 52-week highs on Aug. 21)

  • Acer Therapeutics Inc (NASDAQ: ACER)
  • Avanos Medical Inc (NYSE: AVNS)(Raymond James upgraded the shares from Market Perform to Outperform)
  • Becton Dickinson and Co (NYSE: BDX)
  • BioLife Solutions Inc (NASDAQ: BLFS)
  • DexCom, Inc. (NASDAQ: DXCM)
  • Emergent Biosolutions Inc (NYSE: EBS)
  • Masimo Corporation (NASDAQ: MASI)
  • Medtronic PLC (NYSE: MDT)(reported above-consensus Q2 EPS)
  • Merck & Co., Inc. (NYSE: MRK)
  • Neogen Corporation (NASDAQ: NEOG)
  • Repligen Corporation (NASDAQ: RGEN)
  • Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE: TEVA)
  • Seattle Genetics, Inc. (NASDAQ: SGEN)

Down In The Dumps

(Stocks hitting 52-week lows on Aug. 21)

  • Pain Therapeutics, Inc. (NASDAQ: PTIE)
  • Trinity Biotech plc (ADR) (NASDAQ: TRIB)

See Also: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Stocks In Focus

Allergan Receives CRL For its Uterine Bleeding Medication

Allergan plc (NYSE: AGN) said the FDA issued a complete response letter, or CRL, for its ulipristal acetate for treating abnormal uterine bleeding in women with uterine fibroids.

The company noted that the FDA cited safety concerns regarding ESYMA post-marketing reports outside the U.S.

The stock slid 2.1 percent to $187.10 in after-hours trading.

Myriad Genetics Q4 EPS Beats Estimates; Guidance Trails

Myriad Genetics, Inc. (NASDAQ: MYGN) reported fiscal year fourth-quarter revenues of $200.9 million compared to $199.6 million last year. Adjusted earnings per share rose from 29 cents to 38 cents, ahead of the 33 cents per share consensus estimate. However, the fiscal-year 2019 guidance came in below expectations.

The stock rose 1.07 percent to $43.30 in after-hours trading.

On The Radar

Mallinckrodt PLC (NYSE: MNK) recived a CRL from the FDA on its Stannsoporfin for treating neonates at risk for developing severe hyperbilirubinemia, or severe jaundice. The FDA provided guidance regarding areas of further evaluation for resubmitting Stannsoporfin NDA. Until the company meets with FDA, it doesn't expect to make decision related to future efforts in the development of the product


Related Articles (IBB + MNK)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News FDA Top Stories Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at